# KaliVir Immunotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kalivir-immunotherapeutics

- Industry: Healthcare
- Headquarters: Pittsburgh, US
- Website: www.kalivir.com
- Total disclosed funding: $14M
- Latest round: Series A (Aug 19, 2026)
- Investors on record: 5

## About

Based in Pennsylvania, US, and founded in 2019 by its Chief Science Officer, Stephen Thorne, KaliVir Immunotherapeutics, Inc., operates as a biotechnology company that provides a therapeutic platform for the treatment of cancer patients. In August 2026, KaliVir Immunotherapeutics, Inc. raised USD 14 million in series A funding led by K Partners, with participation from Nextrans and QUAD Investment Management, SV Investment, and Flexus Partners. Helena Chaye currently serving as CEO.


KaliVir offers a potent, novel oncolytic platform called the Vaccinia Enhanced Template (VET™) that can preferentially infect and kill cancer cells. The company also provides oncolytic viral immunotherapy to treat cancer patients with a variety of tumor types.

The company is a clinical-stage biotechnology business and does not publicly disclose commercial product revenue. Based on disclosed activities, its funding sources include venture capital financing, strategic licensing arrangements, research collaborations, and partnership agreements such as its collaboration with Roche and earlier licensing activities involving its viral immunotherapy platform.

The company plans to use March funding to support internal programs with the priority of advancing its lead product candidate into development.

## Funding rounds

- Series A, Aug 19, 2026, $14M — SV Investment, QUAD Investment Management, K Partners, Nextrans
- Series A, Mar 16, 2022 — Premier Partners, QUAD Investment Management, K Partners

## Investors

- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series A
- QUAD Investment Management (https://capitalatlas.ai/funds/quad-investment-management) — Series A
- K Partners (https://capitalatlas.ai/funds/k-partners) — Series A
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A
- Nextrans (https://capitalatlas.ai/funds/nextrans) — Series A